CLINICAL_TRIALS
trial_result
· 2021-03-25
Clinical Trial Update: Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4). [Phase 4]
Summary
Phase 4 clinical trial investigating whether the cardiovascular benefits of empagliflozin are independent of its glucose-lowering effects.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Cardiovascular Diseases | Phase 4 | Status: COMPLETED | Results posted: 2021-03-25